Lonza - Lifescience-Konzern - Älteste Beiträge zuerst (Seite 4)
eröffnet am 27.09.17 13:06:37 von
neuester Beitrag 23.03.24 16:01:59 von
neuester Beitrag 23.03.24 16:01:59 von
Beiträge: 77
ID: 1.262.877
ID: 1.262.877
Aufrufe heute: 2
Gesamt: 10.510
Gesamt: 10.510
Aktive User: 0
ISIN: CH0013841017 · WKN: 928619
530,30
EUR
-0,93 %
-5,00 EUR
Letzter Kurs 22:58:42 Lang & Schwarz
Neuigkeiten
27.04.24 · wO Chartvergleich |
23.04.24 · dpa-AFX |
20.04.24 · wO Chartvergleich |
17.04.24 · wO Newsflash  |
17.04.24 · EQS Group AG |
Werte aus der Branche Chemie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 115,63 | +62,31 | |
| 9,2500 | +48,00 | |
| 31,00 | +38,08 | |
| 43,01 | +22,89 | |
| 33,99 | +22,71 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0100 | -12,63 | |
| 3,6200 | -13,81 | |
| 4,7143 | -13,82 | |
| 7,7500 | -14,17 | |
| 0,9357 | -17,92 |
Feedback
Antwort auf Beitrag Nr.: 58.297.544 von faultcode am 25.07.18 12:30:0225.10.
Lonza Continues Strong Momentum in Businesses Along the Healthcare Continuum in Q3 2018 and Confirms Positive Outlook for the Full Year
• Businesses in Pharma & Biotech and in Consumer Health – including capsule and combined ingredient and dosage form offerings – continued to drive growth
• Announcement of Ibex™ Solutions expansion with new, innovative offerings from preclinical to commercial including fill & finish services was well received
• A challenging environment for cyclical businesses in mature parts of the portfolio continued to have an impact on Consumer & Resources Protection; specialty composites portfolio sustained robust performance
• Outlook for the full year, which was upgraded with Half-Year 2018 results, is confirmed
• Capital Markets Day in September provided strategy update for continued growth toward achieving Lonza’s Mid-Term Guidance 2022 and beyond
Lonza Continues Strong Momentum in Businesses Along the Healthcare Continuum in Q3 2018 and Confirms Positive Outlook for the Full Year
• Businesses in Pharma & Biotech and in Consumer Health – including capsule and combined ingredient and dosage form offerings – continued to drive growth
• Announcement of Ibex™ Solutions expansion with new, innovative offerings from preclinical to commercial including fill & finish services was well received
• A challenging environment for cyclical businesses in mature parts of the portfolio continued to have an impact on Consumer & Resources Protection; specialty composites portfolio sustained robust performance
• Outlook for the full year, which was upgraded with Half-Year 2018 results, is confirmed
• Capital Markets Day in September provided strategy update for continued growth toward achieving Lonza’s Mid-Term Guidance 2022 and beyond
Antwort auf Beitrag Nr.: 59.054.464 von faultcode am 25.10.18 15:31:43
Oberkassel
Lonza verkauft Water Care-Geschäft für 630 Mio USD an Platinum Equity
https://www.finanzen.ch/nachrichten/aktien/lonza-verkauft-wa…Oberkassel
Antwort auf Beitrag Nr.: 59.110.508 von Oberkassel am 01.11.18 08:28:11
Lonza verhält sich zum Gesamtmarkt sehr gut in Europa einer der trendstärksten Werte.
Oberkassel
Lonza plant Entwicklungs- und Produktionsanlage in China
https://www.finanzen.ch/nachrichten/aktien/lonza-plant-entwi…Lonza verhält sich zum Gesamtmarkt sehr gut in Europa einer der trendstärksten Werte.
Oberkassel
Antwort auf Beitrag Nr.: 59.402.784 von Oberkassel am 10.12.18 09:33:55
Lonza weiterhin mit guter Erholung Top Wert in der Schweiz.
Oberkassel
Lonza-Takeda Medikament Alunbrig erhält EU-Marktzulassung
https://www.finanzen.ch/nachrichten/aktien/lonza-takeda-medi…Lonza weiterhin mit guter Erholung Top Wert in der Schweiz.
Oberkassel
Antwort auf Beitrag Nr.: 59.610.662 von Oberkassel am 11.01.19 15:16:30
Heute kleiner Rückschritt wegen Novartis, der Kurs wird sich wieder erholen.
Oberkassel
Aktionäre von Lonza erhalten eine konstante Dividende
http://www.mydividends.de/news/aktionaere-von-lonza-erhalten…Heute kleiner Rückschritt wegen Novartis, der Kurs wird sich wieder erholen.
Oberkassel
Trading Spotlight
Lonza Announces Succession of CEO
• Richard Ridinger to retire• Marc Funk appointed CEO
• Handover as of 1 March 2019
Basel, Switzerland, 30 January 2019 – Lonza announced today that Richard Ridinger, CEO, has decided to retire from the company after seven successful years. Going forward, he intends to build a portfolio of non-executive positions in various companies.
His successor as CEO as of 1 March 2019 will be Marc Funk, currently Chief Operating Officer of the Pharma & Biotech division.
To ensure a seamless transition of leadership, Richard Ridinger will remain with the company until the end of April and will then be available to Lonza in an advisory capacity until the end of 2019...
Antwort auf Beitrag Nr.: 59.744.946 von faultcode am 30.01.19 13:48:21
• Lonza delivered its Full-Year 2018 results with sales of CHF 5.5 billion at a record 27.3% CORE EBITDA margin for Lonza’s continuing operations
• Outperformance in Pharma & Biotech with 14% sales growth and margins up 260 bps was combined with positive momentum in the Consumer Health division
• Lonza continued to benefit from the performance and synergies of the successfully integrated Capsugel businesses, having completed the first full year as a combined company
• The challenging environment for cyclical parts of the Consumer & Resources Protection portfolio continued to have a negative impact on the business throughout the year; countermeasures are being implemented to improve profitability
• Lonza launched further growth initiatives to expand its global and technological footprint, especially in biologics, including the expansion of Ibex™ Solutions in Visp (CH)
• Mid-Term 2022 Guidance confirmed and 2019 Outlook announced
• Review of the business portfolio to be accelerated to further strengthen company’s position along the Healthcare Continuum®
• At the Annual General Meeting, the Board of Directors will propose a stable dividend for shareholders of CHF 2.75 per share for 2018
....
FY2018
Lonza Achieved Another Excellent Full-Year Result in 2018 with 9% Organic Sales Growth and Strong Profitability Driven by Healthcare Businesses• Lonza delivered its Full-Year 2018 results with sales of CHF 5.5 billion at a record 27.3% CORE EBITDA margin for Lonza’s continuing operations
• Outperformance in Pharma & Biotech with 14% sales growth and margins up 260 bps was combined with positive momentum in the Consumer Health division
• Lonza continued to benefit from the performance and synergies of the successfully integrated Capsugel businesses, having completed the first full year as a combined company
• The challenging environment for cyclical parts of the Consumer & Resources Protection portfolio continued to have a negative impact on the business throughout the year; countermeasures are being implemented to improve profitability
• Lonza launched further growth initiatives to expand its global and technological footprint, especially in biologics, including the expansion of Ibex™ Solutions in Visp (CH)
• Mid-Term 2022 Guidance confirmed and 2019 Outlook announced
• Review of the business portfolio to be accelerated to further strengthen company’s position along the Healthcare Continuum®
• At the Annual General Meeting, the Board of Directors will propose a stable dividend for shareholders of CHF 2.75 per share for 2018
....
Antwort auf Beitrag Nr.: 59.744.970 von faultcode am 30.01.19 13:50:31
Oberkassel
Vier Direktoren: Lonza baut um
https://www.handelszeitung.ch/management/vier-direktoren-lon…Oberkassel
Die neue Nummer 2 im Bereich Biopharma-Auftragsnehmer hinter Lonza - FUJIFILM:
-Fujifilm to buy Biogen production site for $890m
-Deal makes Japanese company world's No. 2 biopharma contract manufacturer
https://asia.nikkei.com/Business/Business-deals/Fujifilm-to-…
-Fujifilm to buy Biogen production site for $890m
-Deal makes Japanese company world's No. 2 biopharma contract manufacturer
https://asia.nikkei.com/Business/Business-deals/Fujifilm-to-…
18.4.
Pharma Biotech and Nutrition Businesses Continue to Drive Lonza Performance in Q1 2019
• Continued positive momentum in Pharma Biotech & Nutrition
• All investments in healthcare businesses progressing as planned to further accelerate growth
• Specialty Ingredients continued to face headwinds in Q1 2019
• Measures to mitigate challenges in specialty ingredients businesses under implementation
• Outlook 2019 maintained and accelerated portfolio review ongoing
https://www.lonza.com/about-lonza/media-center/news/Tensid/2…
__
schon älter:
2.4.
Lonza and Chr. Hansen in Joint Venture to Accelerate Momentum in Microbiome
• Two global leaders create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers
• Phased investment of approximately EUR 90 million to be shared equally between the partners over three years
• Headquarters and pharma-grade drug production facility to be established in Switzerland
https://www.lonza.com/about-lonza/media-center/news/Tensid/2…
Pharma Biotech and Nutrition Businesses Continue to Drive Lonza Performance in Q1 2019
• Continued positive momentum in Pharma Biotech & Nutrition
• All investments in healthcare businesses progressing as planned to further accelerate growth
• Specialty Ingredients continued to face headwinds in Q1 2019
• Measures to mitigate challenges in specialty ingredients businesses under implementation
• Outlook 2019 maintained and accelerated portfolio review ongoing
https://www.lonza.com/about-lonza/media-center/news/Tensid/2…
__
schon älter:
2.4.
Lonza and Chr. Hansen in Joint Venture to Accelerate Momentum in Microbiome
• Two global leaders create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers
• Phased investment of approximately EUR 90 million to be shared equally between the partners over three years
• Headquarters and pharma-grade drug production facility to be established in Switzerland
https://www.lonza.com/about-lonza/media-center/news/Tensid/2…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,18 | |
| -0,98 | |
| -0,44 | |
| -1,91 | |
| +0,13 | |
| -0,03 | |
| +3,55 | |
| +0,45 | |
| -0,72 | |
| -0,04 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 262 | ||
| 79 | ||
| 69 | ||
| 69 | ||
| 37 | ||
| 34 | ||
| 26 | ||
| 25 | ||
| 23 | ||
| 22 |
27.04.24 · wO Chartvergleich · AT & S Austria Technologie & Systemtechnik |
23.04.24 · dpa-AFX · Danaher |
20.04.24 · wO Chartvergleich · ABB |
02.04.24 · wO Newsflash · Lonza Group |
02.04.24 · EQS Group AG · Lonza Group |